LIMNLiminatus Pharma, Inc.同业对比
Liminatus Pharma, Inc. 与SIC 2836 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LIMN本股 | $5M#7 | — | — | — | — | -187.8%#14 | — | — | -226.6%#3 | — | — | — |
| CVM | $10M#1 | — | 1.4x#4 | 37.5x#4 | 65.5%#2 | 5.6%#5 | -9396.5%#3 | -369.6%#4 | — | — | — | — |
| BCDA | $9M#2 | — | — | — | -100.0%#6 | -3.5%#6 | — | — | — | — | — | — |
| BKHAR | $7M#4 | — | — | — | — | -30.6%#9 | — | — | — | — | — | 739.8%#1 |
| SLXN | $8M#3 | 0.3x#2 | 26.8x#6 | — | — | 27.9%#3 | — | -4093.5%#6 | — | — | — | — |
| PMCB | $6M#5 | — | 0.2x#1 | — | — | -163.4%#13 | — | -58.3%#1 | -40.0%#1 | — | — | — |
| BCAB | — | 0.4x#3 | — | — | — | -14.6%#8 | -19768.3%#6 | — | — | — | — | — |
| ZIVO | $5M#6 | — | — | 31.3x#3 | 468.6%#1 | -72.1%#10 | -8498.9%#2 | — | — | — | — | — |
| CERO | $4M#8 | — | — | — | — | — | — | — | — | — | — | 2.9%#3 |
| WINT | $3M#10 | — | — | 17.1x#2 | -88.9%#5 | 91.2%#1 | -13201.5%#4 | — | -308.7%#6 | — | — | 19.4%#2 |
| ESLAW | $3M#11 | — | — | — | — | -78.7%#11 | — | — | — | — | — | — |
| CELZ | $3M#12 | — | 0.4x#3 | 419.6x#6 | -45.5%#3 | -9.1%#7 | -102380.2%#7 | -98.1%#2 | -91.0%#2 | 2#1 | — | — |
| LIMNW | $3M#13 | — | — | — | — | -187.8%#14 | — | — | -226.6%#3 | — | — | — |
| HUMAW | $2M#14 | — | 0.2x#2 | 1.1x#1 | — | 72.5%#2 | -5306.0%#1 | -351.3%#3 | — | — | — | — |
| AIM | $4M#9 | — | 1.8x#5 | 42.6x#5 | -48.2%#4 | 19.4%#4 | -13254.5%#5 | -656.8%#5 | — | — | — | — |
| PHGE | $2M#15 | 0.0x#1 | — | — | — | -104.2%#12 | — | — | -250.4%#5 | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-08-02。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议